Huminsulin 30/70 is used to assist in improving glycemic control in adults with diabetes mellitus. Its primary function is to support the maintenance of blood sugar levels within the targeted range throughout the day. This product is generally used by individuals with Type 1 and Type 2 diabetes who require a regimen that incorporates both a rapid-onset and an intermediate-duration component to manage glucose.

This specific fixed ratio is designed to help support a balanced glucose profile, which is a key component of a comprehensive diabetes management plan. This dual-action approach aims to address the body's varying insulin requirements, including the need for a short-term glucose response and a sustained base level of support. The general objective is to contribute to the reduction of hyperglycemia and support a more stable metabolic state.

Quick Fact: Relief for Elevated Blood Glucose Huminsulin 30/70 is utilized to help lower and maintain blood sugar levels in adults diagnosed with diabetes mellitus, supporting a balanced glucose profile.

Who can and cannot use Huminsulin 30/70?

This section outlines the official population eligibility and non-eligibility rules for Huminsulin 30/70 (Insulin Human Biphasic) as defined by government regulatory agencies.

---

Eligibility Scope

Eligibility Scope	Official Regulatory Statement
Populations for whom use is allowed	Adults with Diabetes Mellitus (Type 1 or Type 2) who require improved glycemic control.
Populations for whom use is contraindicated	Patients currently experiencing an episode of hypoglycemia (low blood sugar).
	Patients with known hypersensitivity to insulin human or any of the product's excipients.
Age-related eligibility rules	Safety and effectiveness have not been established in pediatric patients (children and adolescents).
	Older adults may have increased sensitivity, but no overall difference in safety/efficacy was found in clinical trials.
Condition-specific eligibility rules	Patients with renal impairment or hepatic impairment may require careful monitoring and potential dose adjustments.
Pregnancy and lactation status	Use during pregnancy and lactation is acceptable, but requires careful dose adjustment and monitoring.

---

Eligibility-Related Restrictions

• The product is contraindicated for intravenous (IV) administration and must not be used in insulin infusion pumps.
• Concomitant use with Thiazolidinediones (TZDs) requires close patient observation, particularly for those at risk of chronic heart failure.

Regulatory documents define patient eligibility through absolute prohibitions, specific approved populations, and conditional use categories that require careful adjustment for factors like organ function or pregnancy.

Huminsulin 30/70 is a mixed insulin product. The blood sugar lowering effect of insulin can be either increased (leading to hypoglycemia) or decreased (leading to hyperglycemia) by various other medicines.

---

Medicines that Increase the Blood Sugar Lowering Effect

Medicines that enhance the action of insulin and increase the risk of low blood sugar (hypoglycemia) include:

• Other antidiabetic agents (oral or injectable)
• ACE inhibitors (used for high blood pressure or heart failure, e.g., enalapril)
• Salicylates (e.g., aspirin)
• Certain antidepressants (e.g., monoamine oxidase inhibitors or MAOIs)
• Some antibiotics (e.g., sulfonamides)
• Beta-blockers (used for heart conditions and blood pressure, but may also mask hypoglycemia symptoms)

---

Medicines that Decrease the Blood Sugar Lowering Effect

Medicines that reduce the efficacy of insulin and increase the risk of high blood sugar (hyperglycemia) include:

• Corticosteroids (e.g., prednisone)
• Diuretics (e.g., thiazides)
• Thyroid hormones
• Growth hormone
• Certain antipsychotics (e.g., olanzapine, clozapine)
• Sympathomimetics (e.g., epinephrine, salbutamol)

---

️ Important Note

Alcohol, especially when consumed on an empty stomach, can significantly increase the risk of hypoglycemia. Always inform your doctor or pharmacist about all prescription, over-the-counter, and herbal products you are taking to manage potential interactions safely.

Insulin Receptor Binding and Metabolic Signal Initiation

The active insulin component in Huminsulin 30/70 functions as an agonist by binding to and activating the Insulin Receptor (IR), a transmembrane tyrosine kinase receptor located on the surface of target cells, primarily adipocytes (fat), skeletal muscle cells, and hepatocytes (liver). This binding event initiates an intricate intracellular signaling cascade which dictates subsequent metabolic responses.

---

Modulating Glucose Transport and Storage Pathways

The activated signaling cascade leads to the rapid translocation of GLUT4 glucose transporters from the cell interior to the plasma membrane, thereby increasing the cellular uptake of glucose from the bloodstream. Simultaneously, the drug modulates liver metabolism by suppressing pathways responsible for hepatic glucose production (gluconeogenesis and glycogenolysis) and promoting the storage of glucose as glycogen.

---

Dual-Phase Pharmacomechanical Activity Profile

The formulation contains two distinct components—30% soluble insulin and 70% isophane insulin—resulting in a dual-phase pattern of pathway engagement. The soluble insulin provides rapid-onset signaling and high-intensity pathway activation, while the isophane insulin provides a delayed, sustained signaling that influences systemic glucose dynamics over an extended duration.

Preparation and Administration

Huminsulin 30/70 is a suspension of human insulin consisting of both intermediate-acting and rapid-acting components. Proper preparation is necessary to ensure the insulin is mixed uniformly before use.

Resuspending the Insulin

The vial or cartridge should be rotated between the palms of the hands or inverted gently multiple times. This process should continue until the liquid appears uniformly cloudy or milky. It is important to avoid vigorous shaking, as this can cause frothing which may interfere with correct dose measurement. If the suspension remains clumped or if white particles stick to the bottom or walls of the container, the insulin should not be used.

Delivery Methods

This insulin is typically administered via subcutaneous injection. Common injection sites include the abdomen, thighs, buttocks, or the upper arms. The choice of site can influence the speed of absorption, with the abdominal area generally providing the most consistent absorption rate.

• Subcutaneous Injection: The needle is inserted into the fatty tissue just beneath the skin. This medication must not be administered intravenously or intramuscularly.
• Site Rotation: To maintain skin health and ensure consistent insulin absorption, the injection site must be rotated within the chosen body area for every dose. Using the exact same spot repeatedly can lead to localized skin changes such as thickening or pitting.

Timing of Use

Due to the inclusion of a rapid-acting insulin component, Huminsulin 30/70 is generally administered shortly before a meal. This timing helps the insulin action coincide with the rise in blood sugar that occurs after eating. Following the injection, it is necessary to consume a meal or snack containing carbohydrates within the timeframe specified by a healthcare provider.

Research Evidence / Overview of Studies for Huminsulin 30/70

Evidence for Glycemic Control in Diabetes Mellitus

Research explored the formulation’s use in studies evaluating blood glucose levels. This research primarily involves Randomized Controlled Trials (RCTs), where participants are assigned by chance to different treatment groups, as well as Systematic Reviews that combine the results of multiple studies. These studies were generally used in research exploring how blood glucose levels change over time, typically over intermediate observation periods, such as 12 to 24 weeks. The core measure evaluated in these trials is Glycosylated Hemoglobin (HbA1c), a long-term blood glucose marker that studies track.

Research explored the formulation’s evaluation in adult populations, most notably adults with Type 2 Diabetes Mellitus (T2DM). Adults with Type 1 Diabetes Mellitus (T1DM) were also included in some trial designs. Studies reported outcomes related to changes in HbA1c levels measured during the observed time intervals. The formulation was observed in comparative research scenarios against other insulin products.

---

Characterization of the Insulin’s Action Profile (PK/PD Studies)

Research has also examined the fundamental properties of this specific insulin mix through specialized Pharmacokinetic (PK) and Pharmacodynamic (PD) studies. These studies are relevant in evidence describing how insulin action is measured. PK studies examine the drug’s concentration profiles, and PD studies monitor the glucose response over time. These studies are typically short-term, sometimes involving healthy adult volunteers as well as adult patients with Type 2 Diabetes.

---

Study Duration and Long-Term Follow-up

Research focusing on the long-term patterns of this product shows that follow-up durations were limited in many of the core trials. This means there is limited information for long-term outcomes, such as those evaluating glycemic patterns or cardiovascular outcomes over five or more years. Study results reflect the specific conditions under which they were conducted, and the existing evidence largely contributes to understanding symptom patterns over intermediate observation windows of typically less than one year. Consequently, the certainty remains low regarding outcomes that extend well beyond the typical trial period, and long-term effects are not fully established.

---

Gaps and Uncertainties in the Research Landscape

One significant limitation is the product's fixed 30/70 composition, meaning that the research has not explored the separate effects of the two components. Additionally, the variability in how the product is absorbed based on injection site or individual metabolism means that research provides context but not individual predictions regarding the exact timing of peak action. Finally, because sample sizes were modest in some of the foundational studies, the level of certainty remains low in certain subgroup findings. The evidence highlights what is known — and what is still uncertain — regarding this formulation.

Common questions about Huminsulin 30/70 (FAQ)

---

Q: How long does Huminsulin 30/70 last once it’s opened and in use?

According to the official product information, once the product is opened and placed 'in-use,' it is stable for a maximum period of 28 days. The product should be safely discarded after this time, even if some medicine remains.

---

Q: Does Huminsulin 30/70 contain pork or beef products?

This medicine uses human insulin, which is created using recombinant DNA technology. This means the active ingredient is structurally identical to the insulin naturally produced by the human body. However, the final product or specific raw materials used during manufacturing, such as excipients, may include components sourced from non-human origins.

---

Q: What is the difference between Huminsulin 30/70 and other insulin types?

This product is a premixed or fixed-ratio combination insulin. Official documents describe it as containing 30% short-acting soluble insulin and 70% intermediate-acting isophane insulin. This combination is designed to provide both an immediate blood sugar-lowering effect and a sustained, long-lasting effect from a single injection.

---

Q: Is it safe to drink alcohol while using this medicine?

Official information regarding drug interactions notes that alcohol consumption has the potential to affect blood glucose control. Alcohol can potentially increase the blood sugar-lowering effect of insulin, which increases the risk of hypoglycemia (low blood sugar), particularly if consumed on an empty stomach.

---

Q: Can I use a different brand of insulin pen with my Huminsulin 30/70 cartridge?

Regulatory documents and instructions for use generally state that the cartridges for this medicine are designed to be used only with the specific injection pen device recommended by the manufacturer. This is typically due to the risk of incorrect dosing or other administration errors if unauthorized devices are used.

---

Q: How is the dosage for Huminsulin 30/70 determined?

According to official prescribing information, the correct dosage is highly individualized and is determined solely by a healthcare professional. Dosing is adjusted over time based on an individual patient's metabolic needs, which requires regular monitoring of blood glucose levels.

How to Store and Dispose of Huminsulin 30/70

The storage of Huminsulin 30/70 is defined by official regulatory requirements to ensure stability and effectiveness.

Storage Conditions

Condition	Unopened Product	In-Use Product
Temperature	Refrigerate between 2°C and 8°C (36°F and 46°F)	Store below 30°C (86°F)
Freezing/Heat	Must not be frozen; Do not use if frozen	Must not be frozen; Protect from heat
Light Protection	Protect from light	Protect from light

Stability and Safety

Once opened, the product has a maximum in-use period of 28 days, after which it must be discarded. The medicine must be stored out of the sight and reach of children and kept in its original packaging.

Disposal Requirements

Unused or expired medicine must be disposed of according to local requirements. Needles, syringes, and other sharp materials used for administration must be placed immediately in a designated sharps disposal container.